Windtree Q3 net loss $4.1M, licenses KL4 surfactant globally for up to $78.9M milestones

WINDTREE THERAPEUTICS INC /DE/

Net loss of $4.1M ($0.13 per share) vs $8.2M loss in Q3 2021; operating loss $4.7M vs $8.1M.
R&D expenses fell to $1.5M from $4.7M as focus shifts to istaroxime; G&A decreased to $2.7M.
Global license to Lee's (HK)/Zhaoke for KL4 surfactant platform; up to $78.9M milestones plus double-digit royalties.
Cash $8.4M at Sept 30, expected to fund operations into Q2 2023.
USPTO allowed istaroxime patent for longer infusions; positive SEISMiC study published in European Journal of Heart Failure.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

WINDTREE THERAPEUTICS INC /DE/ reported third quarter ended September 30, 2022 results: net income $4.1 million, EPS ($0.13 per basic share).

Period: third quarter ended September 30, 2022
Net income: $4.1 million
EPS: ($0.13 per basic share)
Result: reported results

Exact text from the filing

The Company reported a net loss of $4.1 million ( $0.13 per basic share) on 31.1 million weighted-average common shares outstanding for the quarter ended September 30, 2022 , compared to a net loss of $8.2 million ( $0.31 per basic share) on 26.7 million weighted average common shares outstanding for the comparable period in 2021.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

WINDTREE THERAPEUTICS INC /DE/ filing history →

Source: SEC EDGAR

accession 0001437749-22-027041

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.